Funding for this research was provided by:
Health Technology Assessment Programme (17/65/03)
Received: 6 October 2022
Accepted: 22 November 2022
First Online: 21 December 2022
: Ethical approval was granted by the North West—Liverpool Central Research Ethics Committee on 21 April 2020 (Ref: 20/NW/0113). Due to the COVID-19 pandemic, the trial set-up was paused and the protocol was amended to include the remote patient pathways. Approval for the amended study design was received on 04 May 2021. Written or electronic informed consent to participate will be obtained from all participants.
: Not applicable—no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are available from the corresponding author on request.
: Dr. Janet Wilson reports personal fees from Mundipharma Medical and co-authorship of the UK Guideline on <i>Trichomonas vaginalis</i> and the European guidelines on vaginal discharge and <i>Mycoplasma genitalium</i>. She is the President for the International Union against Sexually Transmitted Infections. Professor Jonathan Ross reports personal fees from GSK Pharma and Bayer Consumer Care and ownership of shares in GSK Pharma and AstraZeneca Pharma and is the lead author of the UK and European Guidelines on Pelvic Inflammatory Disease and a member of the European Sexually Transmitted Infections Guidelines Editorial Board. He is an NIHR Journals Editor and associate editor of the <i>Sexually Transmitted Infections</i> journal. He is a treasurer for the International Union against Sexually Transmitted Infections and chair of charity trustees for the Sexually Transmitted Infections Research Foundation. The other authors declare that they have no competing interests.